Boehringer Ingelheim is Pleased to Welcome Green Light from the National Institute for Health and Care Excellence (NICE) for Its Medicine for Rare Lung Disease.

BRACKNELL, England–(BUSINESS WIRE)–For UK consumer media only

Boehringer Ingelheim is delighted to welcome the news that, following a
full technology appraisal, OFEV▼^® (nintedanib) is now
recommended for use by NICE within the National Health Service (NHS) in
England and Wales.¹

This decision is set to benefit patients across England and Wales and
will provide doctors with a new option for treating the rare lung
disease idiopathic pulmonary fibrosis (IPF).

NICE has recommended OFEV^® for use in adult patients with IPF
who have moderate disease as defined by a predicted forced vital
capacity (FVC) between 50% and 80%. The recommendation states that OFEV^®,
compared to placebo, reduces the decline in lung function in patients
with IPF.¹

The full advice can be found here:

www.nice.org.uk/guidance/ta379

Welcoming the news Professor Klaus Dugi, Medical Director and Managing
Director, BI UK and Ireland said,

“This NICE recommendation for OFEV^® is very welcome news for
patients in England and Wales who have this devastating disease, as it
gives doctors a much needed new option in the management of IPF. At
Boehringer Ingelheim, we have over 90 years of experience in the field
of respiratory medicine and are delighted to be leading the way in
bringing this novel medicine to people with IPF.”

Mr Mike Bray, Chair of Action for Pulmonary Fibrosis, made the following
statement:

“Having been involved in the NICE appraisal process, Action for
Pulmonary Fibrosis is very pleased that nintedanib has been approved for
the treatment of patients with IPF. With no cure and very limited
treatment options, nintedanib offers an alternative therapy which will
be much welcomed by patients.”

About IPF

IPF is a progressive and severely debilitating lung disease with a high
death rate.² It causes progressive scarring of the lungs,
resulting in continual and irreversible deterioration in lung function
and difficulty breathing.³ In patients with IPF, lung
function loss is measured by a decline in a patient’s FVC, the maximum
volume of breath that can be exhaled during a forced breath.

Every year in the UK, more than 5,000 people are diagnosed with the
disease,⁴ with a median survival time of approximately three
years from diagnosis.³

About OFEV^®

OFEV^® is a small molecule tyrosine kinase inhibitor (TKI)
taken orally.⁵ It targets growth factor receptors which
studies have implicated in the pathogenesis of IPF. OFEV^®’s
mechanism of action is thought to occur through inhibiting 3 of these
TKIs; vascular endothelial growth factor receptor (VEGFR), fibroblast
growth factor receptor (FGFR) and platelet‐derived growth factor
receptor (PDGFR).

-ENDS-

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany,
Boehringer Ingelheim operates globally with 146 affiliates and a total
of more than 47,700 employees. The focus of the family-owned company,
founded in 1885, is researching, developing, manufacturing and marketing
new medications of high therapeutic value for human and veterinary
medicine.

Social responsibility is an important element of the corporate culture
at Boehringer Ingelheim. This includes worldwide involvement in social
projects, such as the initiative “Making more Health” and caring for the
employees. Respect, equal opportunities and reconciling career and
family form the foundation of the mutual cooperation. In everything it
does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about
13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its
net sales.

For more information please visit www.boehringer-ingelheim.co.uk.

REFERENCES

1. NICE TA379 – Available at: www.nice.org.uk/guidance/ta379

2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT
statement — idiopathic pulmonary fibrosis: evidence based guidelines for
diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.

3. Idiopathic pulmonary fibrosis in adults: diagnosis and management

NICE guidelines [CG163] Published date: June 2013

Available at: http://www.nice.org.uk/guidance/cg163

Last accessed: January 2016

4. Navaratnam V. The rising incidence of idiopathic pulmonary fibrosis
in the UK. Thorax 2011; 66:462-467.

5. Richeldi L, Costabel U, Selman M. Efficacy of a Tyrosine Kinase
inhibitor in Idiopathic Pulmonary Fibrosis. N Engl J Med 2011;
365:1079-1087

Contacts

Boehringer Ingelheim Limited
Richard Pitt
Corporate Affairs
Manager
Tel: +44 (0)1344 744757
richard.pitt@boehringer-ingelheim.com